Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

The soluble receptor for advanced glycation end products can prospectively identify patients at greatest risk for preterm birth.

Bastek JA, Brown AG, Foreman MN, McShea MA, Anglim LM, Adamczak JE, Elovitz MA.

J Matern Fetal Neonatal Med. 2012 Sep;25(9):1762-8. doi: 10.3109/14767058.2012.663825. Epub 2012 Apr 3.

PMID:
22339587
[PubMed - indexed for MEDLINE]
2.

Detection of feto-maternal infection/inflammation by the soluble receptor for advanced glycation end products (sRAGE): results of a pilot study.

Hájek Z, Germanová A, Koucký M, Zima T, Kopecký P, Vítkova M, Parízek A, Kalousová M.

J Perinat Med. 2008;36(5):399-404. doi: 10.1515/JPM.2008.080.

PMID:
18771410
[PubMed - indexed for MEDLINE]
3.

Maternal serum interleukin-6, C-reactive protein, and matrix metalloproteinase-9 concentrations as risk factors for preterm birth <32 weeks and adverse neonatal outcomes.

Sorokin Y, Romero R, Mele L, Wapner RJ, Iams JD, Dudley DJ, Spong CY, Peaceman AM, Leveno KJ, Harper M, Caritis SN, Miodovnik M, Mercer BM, Thorp JM, O'Sullivan MJ, Ramin SM, Carpenter MW, Rouse DJ, Sibai B.

Am J Perinatol. 2010 Sep;27(8):631-40. doi: 10.1055/s-0030-1249366. Epub 2010 Mar 1.

PMID:
20195952
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation.

Romero R, Espinoza J, Hassan S, Gotsch F, Kusanovic JP, Avila C, Erez O, Edwin S, Schmidt AM.

J Perinat Med. 2008;36(5):388-98. doi: 10.1515/JPM.2008.076.

PMID:
18593373
[PubMed - indexed for MEDLINE]
5.

Soluble receptor for advanced glycation end products in physiological and pathological pregnancy.

Germanová A, Koucký M, Hájek Z, Parízek A, Zima T, Kalousová M.

Clin Biochem. 2010 Mar;43(4-5):442-6. doi: 10.1016/j.clinbiochem.2009.11.002. Epub 2009 Nov 10.

PMID:
19909734
[PubMed - indexed for MEDLINE]
6.

Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients.

Chiang KH, Huang PH, Huang SS, Wu TC, Chen JW, Lin SJ.

Coron Artery Dis. 2009 Jun;20(4):267-73. doi: 10.1097/MCA.0b013e32832c459c.

PMID:
19440065
[PubMed - indexed for MEDLINE]
7.

Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.

Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH.

Atherosclerosis. 2012 Jan;220(1):208-14. doi: 10.1016/j.atherosclerosis.2011.07.115. Epub 2011 Aug 5.

PMID:
21906738
[PubMed - indexed for MEDLINE]
8.

sRAGE is elevated in septic patients and associated with patients outcome.

Bopp C, Hofer S, Weitz J, Bierhaus A, Nawroth PP, Martin E, Büchler MW, Weigand MA.

J Surg Res. 2008 Jun 1;147(1):79-83. Epub 2007 Aug 22.

PMID:
17981300
[PubMed - indexed for MEDLINE]
9.

Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity.

Sternberg Z, Weinstock-Guttman B, Hojnacki D, Zamboni P, Zivadinov R, Chadha K, Lieberman A, Kazim L, Drake A, Rocco P, Grazioli E, Munschauer F.

Mult Scler. 2008 Jul;14(6):759-63. doi: 10.1177/1352458507088105. Epub 2008 May 27.

PMID:
18505774
[PubMed - indexed for MEDLINE]
10.

Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients.

Jabaudon M, Futier E, Roszyk L, Chalus E, Guerin R, Petit A, Mrozek S, Perbet S, Cayot-Constantin S, Chartier C, Sapin V, Bazin JE, Constantin JM.

Crit Care Med. 2011 Mar;39(3):480-8. doi: 10.1097/CCM.0b013e318206b3ca.

PMID:
21220996
[PubMed - indexed for MEDLINE]
11.

Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes.

Yu Y, Hanssen KF, Kalyanaraman V, Chirindel A, Jenkins AJ, Nankervis AJ, Torjesen PA, Scholz H, Henriksen T, Lorentzen B, Garg SK, Menard MK, Hammad SM, Scardo JA, Stanley JR, Wu M, Basu A, Aston CE, Lyons TJ.

BJOG. 2012 Nov;119(12):1512-20. doi: 10.1111/j.1471-0528.2012.03463.x. Epub 2012 Aug 20.

PMID:
22900949
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Clinical significance of serum sRAGE and esRAGE in women with normal pregnancy and preeclampsia.

Kwon JH, Kim YH, Kwon JY, Park YW.

J Perinat Med. 2011 Sep;39(5):507-13. doi: 10.1515/JPM.2011.055. Epub 2011 Jul 18.

PMID:
21767223
[PubMed - indexed for MEDLINE]
13.

Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.

Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ.

Diabetologia. 2006 Nov;49(11):2756-62. Epub 2006 Sep 13.

PMID:
16969649
[PubMed - indexed for MEDLINE]
14.

Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products.

McNair ED, Wells CR, Mabood Qureshi A, Basran R, Pearce C, Orvold J, Devilliers J, Prasad K.

Mol Cell Biochem. 2010 Aug;341(1-2):135-8. doi: 10.1007/s11010-010-0444-3. Epub 2010 Mar 27.

PMID:
20339904
[PubMed - indexed for MEDLINE]
15.

Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction.

Christie JD, Shah CV, Kawut SM, Mangalmurti N, Lederer DJ, Sonett JR, Ahya VN, Palmer SM, Wille K, Lama V, Shah PD, Shah A, Weinacker A, Deutschman CS, Kohl BA, Demissie E, Bellamy S, Ware LB; Lung Transplant Outcomes Group.

Am J Respir Crit Care Med. 2009 Nov 15;180(10):1010-5. doi: 10.1164/rccm.200901-0118OC. Epub 2009 Aug 6.

PMID:
19661249
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Detection of interleukin-6 in maternal plasma predicts neonatal and infectious complications in preterm premature rupture of membranes.

Lewis DF, Barrilleaux PS, Wang Y, Adair CD, Baier J, Kruger T.

Am J Perinatol. 2001 Nov;18(7):387-91.

PMID:
11731892
[PubMed - indexed for MEDLINE]
17.

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.

Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T.

Microvasc Res. 2008 May;76(1):52-6. doi: 10.1016/j.mvr.2007.09.004. Epub 2007 Oct 5.

PMID:
18474381
[PubMed - indexed for MEDLINE]
18.

Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D.

Arterioscler Thromb Vasc Biol. 2005 May;25(5):1032-7. Epub 2005 Feb 24.

PMID:
15731496
[PubMed - indexed for MEDLINE]
Free Article
19.

Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.

Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T.

Metabolism. 2006 Sep;55(9):1227-31.

PMID:
16919543
[PubMed - indexed for MEDLINE]
20.

Soluble receptor for advanced glycation endproducts is decreased in patients with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels.

Myles A, Viswanath V, Singh YP, Aggarwal A.

J Rheumatol. 2011 Sep;38(9):1994-9. doi: 10.3899/jrheum.110058. Epub 2011 Jul 1.

PMID:
21724696
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk